News articles about Baxter International (NYSE:BAX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxter International earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.0376502281626 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Baxter International Inc.: Baxter Expands Voluntary Nationwide Recall to … (twst.com)
- Technical Facts for Investment in Baxter International Inc. (BAX) – Wall Street Morning (wallstreetmorning.com)
- Optimistic Trending Companies: BorgWarner Inc. (BWA), Baxter International Inc. (BAX) – Market Movers (financialqz.com)
- Baxter (BAX) Launches Arisure Closed System Transfer Device – Nasdaq (nasdaq.com)
- Hospitals find other ways to deliver medicine amid IV bag shortage – WHAS 11.com (whas11.com)
Several equities research analysts have recently weighed in on BAX shares. Zacks Investment Research raised shares of Baxter International from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Royal Bank of Canada reissued a “hold” rating and issued a $60.00 target price on shares of Baxter International in a research report on Tuesday, October 3rd. Cowen set a $68.00 target price on shares of Baxter International and gave the stock a “hold” rating in a research report on Sunday, October 15th. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Finally, Evercore ISI started coverage on shares of Baxter International in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price for the company. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $68.64.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the firm earned $0.56 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. sell-side analysts expect that Baxter International will post 2.43 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date was Thursday, November 30th. Baxter International’s dividend payout ratio is presently 34.59%.
In related news, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Third Point Llc sold 5,000,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $64.23, for a total transaction of $321,150,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,061,991 shares of company stock valued at $325,245,035. Insiders own 0.05% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.